Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals, sold LGND on Aug 3, 2026
Data as of Oct 16
- Traded
- Aug 3, 2026
- Disclosed
- Aug 4, 2026
- Filed
- 1 day after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
LGND since disclosure
−1.7%
after the sale
Similar stocks (XLV) since disclosure
+9.0%
XLV — its sector index fund
Change in closing price from Aug 4, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$296Kdisclosed Aug 4 · filed 1 day after the trade
- ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$44.9Kdisclosed Aug 4 · filed 1 day after the trade
- ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$29.8Kdisclosed Aug 4 · filed 1 day after the trade
- ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$289Kdisclosed Aug 4 · filed 1 day after the trade
- ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$9.4Kdisclosed Aug 4 · filed 1 day after the trade
- ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$349Kdisclosed Aug 4 · filed 1 day after the trade
- ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$146Kdisclosed Aug 4 · filed 1 day after the trade
- ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$58.1Kdisclosed Aug 4 · filed 1 day after the trade
- ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$120Kdisclosed Aug 4 · filed 1 day after the trade